Solventum Corporation $SOLV Shares Acquired by Corient Private Wealth LLC

Corient Private Wealth LLC boosted its stake in Solventum Corporation (NYSE:SOLV) by 18.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,092 shares of the company’s stock after buying an additional 7,653 shares during the period. Corient Private Wealth LLC’s holdings in Solventum were worth $3,859,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Hilltop National Bank boosted its position in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares in the last quarter. CrossGen Wealth LLC bought a new stake in Solventum during the fourth quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in Solventum in the third quarter worth approximately $25,000. JNBA Financial Advisors grew its position in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after buying an additional 228 shares during the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in shares of Solventum in the second quarter valued at $28,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on SOLV shares. Wedbush initiated coverage on Solventum in a research note on Friday, May 15th. They set an “outperform” rating and a $94.00 price objective for the company. Piper Sandler reduced their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. BTIG Research reiterated a “buy” rating and issued a $89.00 target price on shares of Solventum in a report on Wednesday, May 6th. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Wells Fargo & Company dropped their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $84.25.

Solventum Trading Up 2.1%

Solventum stock opened at $79.56 on Friday. The business has a 50 day moving average price of $74.58 and a two-hundred day moving average price of $74.62. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20. The stock has a market cap of $13.78 billion, a price-to-earnings ratio of 9.75, a price-to-earnings-growth ratio of 1.20 and a beta of 0.69.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.